

[nRichDX unveils high-yield liquid biopsy sample prep platform](#)

written by CAP TODAY
September 26, 2019

Sept. 26, 2019—[nRichDX](#) introduced its Revolution System, a high-yield sample prep platform designed to increase liquid biopsy-based test sensitivity by delivering more target input for molecular assays. The target yield increase is accomplished by combining the ability to process a wide range of sample volumes (3-50 mL) with recovery rates of 70-90 percent.

“After three years of development, we are very excited to introduce our Revolution System,” William Curtis, CEO of nRichDX, said in a company press release. “The data that we’ve developed in collaboration with early adopters like Dr. Greg Tsongalis of Dartmouth-Hitchcock Medical Center and Dr. Ryan Corcoran of Massachusetts General Hospital are highly compelling. We are confident that our Revolution System will advance the promise of precision medicine by enabling a significant increase in liquid biopsy-based test sensitivity.”

The system’s initial application is for the extraction of cfDNA from plasma and urine. Applications for CTCs, exosomes, and total cell-free nucleic acid are in development.



©2026 CAP TODAY, all rights reserved.